Lauren Riker Sells 1,416 Shares of Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) SVP Lauren Riker sold 1,416 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $24.24, for a total transaction of $34,323.84. Following the transaction, the senior vice president directly owned 59,064 shares of the company’s stock, valued at $1,431,711.36. The trade was a 2.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Pacira BioSciences Trading Up 0.8%

NASDAQ:PCRX traded up $0.21 during trading hours on Tuesday, reaching $25.31. 534,727 shares of the stock were exchanged, compared to its average volume of 813,509. Pacira BioSciences, Inc. has a twelve month low of $18.18 and a twelve month high of $27.64. The business has a 50-day moving average of $24.30 and a two-hundred day moving average of $24.22. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of 56.25 and a beta of 0.22. The company has a quick ratio of 3.78, a current ratio of 5.26 and a debt-to-equity ratio of 0.52.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. The firm had revenue of $179.52 million for the quarter, compared to analyst estimates of $182.86 million. Pacira BioSciences had a return on equity of 12.82% and a net margin of 2.99%.Pacira BioSciences’s revenue was up 6.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.79 EPS. On average, equities analysts predict that Pacira BioSciences, Inc. will post 2.41 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on PCRX shares. Wall Street Zen raised Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of Pacira BioSciences in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Truist Financial reduced their price objective on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Finally, Barclays initiated coverage on shares of Pacira BioSciences in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $27.00 price objective for the company. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and a consensus target price of $28.20.

Institutional Trading of Pacira BioSciences

Several institutional investors and hedge funds have recently made changes to their positions in PCRX. Gagnon Advisors LLC raised its stake in shares of Pacira BioSciences by 60.0% during the 2nd quarter. Gagnon Advisors LLC now owns 213,402 shares of the company’s stock worth $5,100,000 after buying an additional 80,012 shares in the last quarter. Exchange Traded Concepts LLC purchased a new position in Pacira BioSciences in the third quarter worth $1,948,000. KLP Kapitalforvaltning AS lifted its holdings in Pacira BioSciences by 48.5% in the second quarter. KLP Kapitalforvaltning AS now owns 35,200 shares of the company’s stock valued at $841,000 after acquiring an additional 11,500 shares during the period. American Century Companies Inc. boosted its position in shares of Pacira BioSciences by 77.2% during the 2nd quarter. American Century Companies Inc. now owns 1,182,513 shares of the company’s stock worth $28,262,000 after purchasing an additional 515,090 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of Pacira BioSciences by 1,503.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 8,160 shares of the company’s stock worth $195,000 after purchasing an additional 7,651 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.